Dupilumab treatment reduces serum SCCA2 levels in patients with atopic dermatitis

IF 1.1 Q4 ALLERGY

Journal of Cutaneous Immunology and Allergy Pub Date : 2022-10-17 DOI:10.1002/cia2.12282

Kanako Kita MD, Yasutomo Imai MD, PhD, Makoto Nagai MD, PhD, Masaru Natsuaki MD, PhD, Nobuo Kanazawa MD, PhD

引用次数: 0

Abstract

Dupilumab treatment reduced serum SCCA2 levels in patients with atopic dermatitis. Interestingly, even though the skin eruptions had not yet fully disappeared, serum SCCA2 levels were reduced well to below normal by the administration of dupilumab.

Abstract Image

查看原文本刊更多论文

Dupilumab治疗降低特应性皮炎患者血清SCCA2水平

杜匹单抗治疗可降低特应性皮炎患者血清SCCA2水平。有趣的是，即使皮肤皮疹还没有完全消失，血清SCCA2水平在使用杜匹单抗后也降低到正常水平以下。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cutaneous Immunology and Allergy Medicine-Dermatology

CiteScore

0.60

自引率

10.00%

发文量

审稿时长

12 weeks